Single-agent paclitaxel in patients with previously untreated stage IV epithelial ovarian cancer
1997

Paclitaxel for Stage IV Ovarian Cancer

Sample size: 36 publication Evidence: moderate

Author Information

Author(s): ME Gore, G Rustin, M Slevin, C Gallagher, R Penson, R Osborne, J Ledermann, T Cameron, JM Thompson

Primary Institution: Royal Marsden Hospital

Hypothesis

Single-agent paclitaxel will be effective in patients with previously untreated stage IV epithelial ovarian cancer.

Conclusion

High-dose paclitaxel is active and well tolerated in patients with stage IV epithelial ovarian cancer.

Supporting Evidence

  • One patient had a complete response and 12 patients had partial responses.
  • The overall response rate was 39.4%.
  • The median survival of patients was 17.2 months.
  • Neutropenia was the main toxicity encountered, with 31% of patients experiencing grade 3 and 19% grade 4.
  • 78% of patients experienced noticeable alopecia.

Takeaway

This study tested a medicine called paclitaxel on patients with a serious type of cancer, and it helped some of them feel better for a while.

Methodology

Patients received paclitaxel intravenously at a dose of 225 mg/m² on a 21-day cycle for six courses.

Potential Biases

Selection bias may have occurred due to including only patients with good performance status.

Limitations

The study included only patients with measurable disease, which may not represent all patients with stage IV cancer.

Participant Demographics

Median age of participants was 57 years, with a range of 20-73 years.

Statistical Information

Confidence Interval

95% CI 23-58%

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication